Search by keywords: and/or Search by cancer type: Thoracic-Lung Cancer [5]--Lung Cancer, Non-Small Cell [62]---Lung Adenocarcinoma [2]---Other [4]--Lung Cancer, Small Cell [8] Narrow your choices Trial phase: - Any -Pilot (small research study)Phase I (phase 1)Phase I/II (phases 1 and 2 combined)Phase II (phase 2)Phase II/III (phases 2 and 3 combined)Phase III (phase 3)Phase IV (phase 4)N/APhase III/IV (phases 3 and 4 combined)Phase 0 (very small research study) Reset 72 Clinical Trials found A Phase 3 Study of Ivonescimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as Initial Treatment for Advanced Lung Cancer Researchers are measuring the safety of ivonescimab when given with standard lung cancer treatments and seeing how well it works. The people in this study have been newly diagnosed with squamous non-small cell lung cancer that has metastasized (spread). New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase 3 Study of Ivonescimab Versus Pembrolizumab Immunotherapy for the Initial Treatment of Metastatic Non-Small Cell Lung Cancer Researchers are comparing ivonescimab with pembrolizumab immunotherapy for the initial treatment of advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has metastasized (spread). New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase 3 Study of LY3537982, Pembrolizumab Immunotherapy, and Other Standard Therapies in People With Advanced Non-Small Cell Lung Cancer Researchers are doing this study to see if giving LY3537982 with standard lung cancer drugs is safe and works well. The people in this study have non-small cell lung cancer that has spread. In addition, their cancers have a gene mutation (change) called KRASG12C, which can cause cancer cells to grow. New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase 3 Study of Olomorasib Plus Immunotherapy in People With Stage 2 or 3 Non-Small Cell Lung Cancer In addition, their cancers have a mutation (change) in the G12C location of the KRAS gene. Olomorasib may help slow or stop the growth of cancers with KRAS G12C mutations. It is taken orally (by mouth). New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase 3 Study of RMC-6236 Versus Docetaxel in People With Advanced Non-Small Cell Lung Cancer Researchers are comparing RMC-6236 with docetaxel for the treatment of lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread beyond its original location. In addition, their tumors have a mutation (change) in the RAS gene. New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase 3 Study of Taletrectinib versus Placebo in People with Non-Small Cell Lung Cancer After Complete Tumor Removal Researchers are comparing taletrectinib with a placebo (inactive drug) in people with non-small cell lung cancer (NSCLC). The people in this study have stage 1B-3A NSCLC that has a ROS1 gene fusion. They have had the tumor completely removed with surgery. New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase 3 Study of V940 Plus Pembrolizumab Immunotherapy After Surgery in People With Non-Small Cell Lung Cancer Researchers are assessing a personalized cancer vaccine called V940 plus pembrolizumab immunotherapy to prevent lung cancer recurrence. The people in this study had surgery to remove non-small cell lung cancer (NSCLC), followed by chemotherapy. New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase 3 Study of V940 Plus Pembrolizumab Immunotherapy in People With Non-Small Cell Lung Cancer V940 is made in a laboratory. It uses genes in your cancer to teach your immune system to fight the cancer. V940 is given as an injection into a muscle. Pembrolizumab boosts the ability of the immune system to find and kill cancer cells. It is given intravenously (by vein). New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase I Study of BCA101, Alone and Combined with Pembrolizumab Immunotherapy, in People with Advanced Lung Cancer The purpose of this study is to find the highest dose of the investigational drug BCA101 that can be given safely alone and in combination with the immunotherapy drug pembrolizumab in patients with advanced lung cancer that cannot be cured with standard treatments. BCA101 is an antibody that targets two proteins involved in cancer growth called EGFR and TGF-beta. By blocking these proteins, BCA101 may interfere with the signals that spur cancer growth.  New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau A Phase I Study of NVL-520 in People with Solid Tumors The purpose of this study is to find the highest dose of the investigational drug NVL-520 that can be given safely in people with metastatic solid tumors that contain a change (fusion) involving the ROS1 gene. A fusion gene is made when parts of two different genes join together. NVL-520 blocks the ROS1 protein, which promotes cancer cell growth and survival. It is taken orally (by mouth New York City, Commack, Westchester, Monmouth Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Next page Next › Last page Last »